Analysis
Is compounded semaglutide the same as Ozempic or Wegovy?
No: a compounded semaglutide prescription is a different product from Ozempic or Wegovy. Compare ingredient descriptions, pharmacy identity, forms and purchasing terms.
Claims are checked against the sources cited in this article. Nothing here is individualized medical advice. How we research
On this page
No. A compounded semaglutide prescription is not the branded Ozempic or Wegovy product, even if the seller describes semaglutide as its active ingredient. Product identity, pharmacy preparation, formulation and regulatory status must be distinguished before comparing the prices.
Sources checked October 9, 2026. This is a product and purchasing comparison, not a conclusion about clinical equivalence, safety or which treatment to choose.
One ingredient name does not identify the whole product
“Semaglutide” can appear in an ingredient description, a branded medicine’s information or a telehealth advertisement. It does not, by itself, tell you which finished product you would receive. An offer for Ozempic or Wegovy should identify the branded product; a compounded offer should identify the compounded prescription and preparing pharmacy.
FDA warns about telehealth claims that a compounded drug is the same as an FDA-approved drug. It also reports fraudulent products whose labels named pharmacies that did not prepare them. This is why an actual product description matters more than a marketing phrase such as “like Ozempic.” FDA’s concerns about unapproved GLP-1 products
The first comparison is therefore factual: what is being sold? If a consultation page discusses a familiar brand but the prescription is compounded, keep those descriptions separate. Ask the service to explain the product it supplies rather than inferring it from the condition discussed or the headline price.
A practical product-identity checklist
| Detail | What to establish |
|---|---|
| Exact name | Branded Ozempic or Wegovy, or a specifically identified compounded prescription |
| Ingredient description | The exact active ingredient and any additional ingredients |
| Form | Injection, tablet or another stated form; do not assume forms are interchangeable |
| Preparing organization | Manufacturer for a branded product; named compounder for a compounded prescription |
| Dispensing organization | The actual pharmacy filling your prescription |
| Price scope | Medicine, consultation, required subscription, shipping and any separate charges |
This checklist helps organize the offer. It does not establish that one formulation has the same effects as another, or tell you how to use either product. Our semaglutide guide provides links for understanding offerings, while the prescription and pharmacy should supply the details of your actual order.
Compounded is not the same as an approved generic
FDA explicitly distinguishes compounded drugs from approved generics. A compounded prescription has not gone through FDA’s premarket review for safety, effectiveness and quality. Calling it “generic Ozempic” does not make it an approved generic or the branded product. FDA’s compounding questions and answers
Approval status is one difference, but it is not the only information a shopper needs. The actual ingredient description, additional components, prescription-specific paperwork and supplier also matter. A pharmacy license verifies a different kind of record from a drug approval, and an outsourcing facility’s registration concerns that facility rather than every product it prepares.
Those distinctions should remain visible in a cost comparison. A lower price is a purchasing fact; it does not establish that the quoted compounded prescription is an approved substitute or clinically equivalent to another medicine.
Why semaglutide salts need a separate answer
FDA identifies semaglutide sodium and semaglutide acetate as different active ingredients from the one used in approved drugs. The agency says it is unaware of a lawful basis for using those salts in compounding. A general assurance that the product contains semaglutide is therefore not enough to settle the ingredient question. FDA’s salt-form explanation
Request the precise name recorded on the prescription and pharmacy documentation. If the seller’s page and paperwork describe different ingredients, ask for an explanation. Do not use the advertised name to resolve uncertainty about an actual label, and do not try to judge a product’s composition from its appearance.
What about semaglutide with B12?
An additional ingredient makes the formulation description different; it does not answer whether the product is equivalent to Ozempic or Wegovy. It also does not automatically satisfy the federal conditions for compounding. FDA’s April 1, 2026 clarification gives semaglutide combined with B12 as an example that can still be considered essentially a copy under the agency’s ingredient, strength and route analysis. FDA’s compounding-policy clarification
For an administrative comparison, record all the stated ingredients and ask the prescriber or pharmacist what the prescription actually specifies. Do not interpret “with B12” as an approval label, a guaranteed exception or evidence of an added clinical benefit. Those are separate claims requiring separate support.
Why old shortage descriptions can confuse the comparison
FDA determined that the semaglutide injection shortage was resolved on February 21, 2025, and later described the end of shortage-related transition periods. Those policies addressed compounding conditions, not whether compounded products became the branded medicines. FDA’s shortage timeline
An older offer may have been written in that shortage context. Check the source date and current product description rather than assuming its explanation still applies. A pharmacy’s local inventory problem is also not itself an FDA national shortage determination.
How to compare the payments without comparing clinical effects
Place the offers side by side using the same purchasing period. Record what each quoted payment buys, whether medication is included, the required commitment, any separate shipping or consultation charge and how cancellation affects future billing. Identify promotional and ongoing amounts separately.
Our compounded semaglutide price comparison reports reviewed compounded offers with their stated conditions. It does not rank them as equivalent to Ozempic or Wegovy. The company profiles help trace services to their published information; neither inclusion nor price establishes regulatory or clinical equivalence.
Those compounded injection records cover Gentle Health, Mochi Health, OrderlyMeds and Henry Meds. For instance, Gentle’s pricing page separates compounded oral drops from injection tiers; a general semaglutide heading is therefore insufficient to identify the purchased form. Apply that same check to each provider’s quote rather than treating an oral, injectable or branded offer as the same transaction.
If you cannot tell which product a quote covers, clarify that before deciding the offer is cheaper. Comparing a membership fee with another service’s medication-inclusive payment produces a misleading result even before considering the different product identities.
The bottom line: compounded semaglutide, Ozempic and Wegovy should not be treated as the same finished product. Compare the actual formulation, preparing pharmacy and payment terms, and leave questions about treatment selection and clinical equivalence to qualified professionals.